Podcast Episodes
Back to Search
273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter
Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters th…
3 years, 1 month ago
272: Vivek's star turn, leaky drug data, & biotech as family business
We discuss how Vivek Ramaswamy, fresh off his headline-grabbing debut at the first Republican presidential debate, went from a drug industry entrepre…
3 years, 2 months ago
271: Racing for gene therapy, a pioneering approval, & startups in the lurch
Our colleague Jason Mast joins us to explain how the approval of a landmark gene therapy for Duchenne muscular dystrophy set in motion a frantic race…
3 years, 2 months ago
270: Your guide to Wegovy’s blockbuster heart study
In the wake of a massively important clinical trial of Novo Nordisk’s obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know…
3 years, 2 months ago
269: Biotech layoffs, eye drug drama, & gene therapy milestones
First, we discuss how some recent layoffs and a reverse merger mean for biotech in 2023. We’ll also discuss the latest news in the life sciences, inc…
3 years, 2 months ago
268: Biogen's sticky situation, Wegovy's risks, & biotech insider trading
First, we discuss why Wall Street was less than convinced by Biogen's attempt to assuage concerns about its credibility. Then we explain an insider t…
3 years, 3 months ago
267: BridgeBio's big week, Lilly's Alzheimer's data, & succession at Stanford
Neil Kumar, CEO of BridgeBio, joins us to talk about how his small company came to develop what could be a big drug — and why classical Greek literat…
3 years, 3 months ago
266: Wegovy in the brain, pivotal Alzheimer's data, & pulling Threads
Our colleague Megan Molteni joins us to explain the evolving science suggesting products like Wegovy are less weight loss drugs than treatments for h…
3 years, 3 months ago
265: Novavax's CEO promises a turnaround & how Lilly roiled the obesity market
Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lill…
3 years, 4 months ago
264: Messy PBM conflicts, debatable vaccines, & the future of flu season
Our colleague Bob Herman joins us to explain his year-long investigation into some brazen conflicts of interest in the world of prescription drug pri…
3 years, 4 months ago